News Search Results
Dec 02, 2025, 13:00 ET The VA Disability System Is Failing -- and Veterans Are Paying for the Gaps By Loren Ryan Hawley
VA disability program as an "honor system" heavily reliant on veterans self-reporting symptoms — particularly for conditions like PTSD, migraines, insomnia, chronic pain, depression, and Gulf War illnesses.Yet in reality, the VA often treats those same self-reports with skepticism:C&P
More news about: Odin Industries LLC
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
more frequently than on placebo were somnolence, decreased appetite, agitation, ataxia, decreased weight, hypotonia, nausea, tremor, dysarthria, and insomnia.PREGNANCYThere are no adequate data on the developmental risks associated with the use of DIACOMIT in pregnant women. Based on
More news about: Biocodex, Inc.
Nov 25, 2025, 10:15 ET Dietary Supplements Market to Hit $414.5B by 2033, Growing at 8.9% CAGR - Key Trends & Insights by Grand View Research, Inc.
Detox/CleanseSkin/ Hair/ NailsSexual HealthBrain/Mental HealthInsomniaMenopauseAnti-agingPrenatal HealthOthersDietary
More news about: Grand View Research, Inc.
Nov 25, 2025, 09:29 ET CreatorFi Launches on Aptos with $2M Strategic Backing to Scale Stablecoin Credit for Creators
amplifying Aptos' mission to become the home for onchain finance and cross-border digital money movement.About CreatorFiCreatorFi, by Insomnia Labs, is a fintech platform that transforms digital media revenue into credit-ready assets, providing creators, studios, and media businesses
More news about: CreatorFi
Nov 25, 2025, 09:00 ET Insomnia Cookies Celebrates National Cookie Day with FREE Cookies for a Year
Download Insomnia Cookies images here.About Insomnia Cookies Insomnia Cookies is a rapidly expanding late-night bakery concept headquartered in Philadelphia, PA. Founded at the University of Pennsylvania by then-student Seth Berkowitz, Insomnia Cookies has been
More news about: Insomnia Cookies
Nov 25, 2025, 05:00 ET AI Detects First Imaging Biomarker of Chronic Stress
Chronic stress can affect both physical and psychological well-being, causing a variety of problems including anxiety, insomnia, muscle pain, high blood pressure and a weakened immune system, according to the American Psychological Association. Research shows that chronic stress
More news about: Radiological Society of North America (RSNA)
Nov 24, 2025, 08:56 ET Izzatov's Secret Rejuvenation Center Launches "5 Step Sleep Tantra": Revolutionary Sleep Restoration Method
individuals achieve rapid, deep, and restorative sleep. This systematic approach offers a powerful, long-term solution for those battling chronic insomnia, anxiety, and sleep deprivation. The "5-Step Sleep Tantra" moves beyond standard sleep hygiene advice. Developed by Master Izzatov, Founder
More news about: Izzatov's Secret Rejuvenation Center
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
fatal events in 0.2%. The most frequent neurologic toxicities were dysgeusia (34%), headache (17%), peripheral neuropathy (9%), dizziness (9%), and insomnia (8%). The incidence of signs and symptoms consistent with ICANS was 10% in IMDELLTRA®-treated patients including events with the preferred
More news about: Amgen
Nov 19, 2025, 09:00 ET Insomnia Cookies Marks 350 Locations in Ongoing Global Expansion
Download Insomnia Cookies images here. About Insomnia Cookies Insomnia Cookies is a category-disrupting late-night
More news about: Insomnia Cookies
Nov 18, 2025, 08:00 ET Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Nov 17, 2025, 08:04 ET SK Life Science, Inc. Announces Publication of C035 Study Analyses in Epilepsia and Seizure
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 13, 2025, 16:18 ET How to Talk to Your Doctor about CBD
of Medicine's comprehensive biomedical literature database. Start with broad terms like "cannabidiol" or "CBD," and refine with specifics such as insomnia, anxiety, aching joints, addiction. Filter for "clinical trials," "case reports," or "systematic reviews" to find specific types of evidence. Systematic
More news about: Fusion CBD Products
Nov 13, 2025, 10:15 ET Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP)
levels. Most common adverse reactions (≥ 5 percent) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis. Please see full
More news about: Ingenus Pharmaceuticals LLC
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 05:00 ET VISTAJET LAUNCHES THE SLEEP PROGRAM -- A SCIENCE-BACKED APPROACH TO REST AND RECOVERY AT ALTITUDE AND AT DESTINATION
performance to transform rest in-flight into a restorative advantage. As research continues to show that over one-third of adults experience insomnia[1] and over half experience poor sleep quality[2], VistaJet addresses a true demand for supportive travel solutions,
More news about: VistaJet
Nov 11, 2025, 16:24 ET Empower Mental Health & Wellness Clinic Opens Doors in Kenosha: Offering Mental Health Treatment and Physical Therapy
pain. As part of its launch, Empower will offer EXOMIND TMS, a noninvasive intervention to treat depression, reduce anxiety and food cravings, treat insomnia, and improve cognition and overall wellness.
More news about: Empower Mental Health & Wellness Clinic
Nov 10, 2025, 06:00 ET Headspace for Cigna Healthcare Enhances Everyday Mental Health Support Through Self-Guided, Science Backed Resources
depression symptoms after just 30 days. Participants in the Headspace Sleep Program also reported a 29% reduction in insomnia symptoms among adults with clinical, self-reported insomnia. Headspace and Cigna Healthcare will collaborate to develop custom content exclusively for Cigna customers.
More news about: Cigna Healthcare
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, rash, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, musculoskeletal pain, upper respiratory tract infection, peripheral
More news about: Johnson & Johnson
Nov 04, 2025, 09:00 ET Kong Releases Insomnia 12 to Accelerate API and MCP Development with AI-Powered Testing and Collaboration
cloud API and AI technologies, announced today the general availability of Insomnia 12, the open source API development platform that unifies designing, mocking, debugging, and testing APIs. The new release focuses on making Insomnia smarter, faster, and more accessible for developers building APIs and Model
More news about: Kong Inc.
Oct 29, 2025, 13:49 ET Marquez Medical Aesthetic Showcasing EXOMIND Technology for Mental and Physical Health
Oct. 29, 2025 /PRNewswire/ -- Individuals seeking a noninvasive treatment for depression, anxiety, obsessive-compulsive disorder, insomnia and brain fog may benefit from EXOMIND, a new brain stimulation treatment now available at Marquez Medical Aesthetic in Hialeah. Research shows EXOMIND
More news about: Marquez Medical Aesthetic
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
stomach (abdominal) pain diarrhea difficulty sleeping (insomnia) back pain hot flashes or hot flushes These are
More news about: Astellas Pharma Inc.
Oct 20, 2025, 21:20 ET SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Biopharmaceuticals. Co., Ltd.
Oct 20, 2025, 08:00 ET Elektra Health and Oscar Launch HelloMeno the First-Ever Menopause Health Plan in the Individual Market
$0 primary doctor, gynecologist, and behavioral health visits. No-cost labs, hormone replacement therapy, insomnia medications, and bone density scans. 24/7 access to Elektra and a team of doctors who know menopause inside and out2
More news about: Elektra Health